Portal de Periódicos da CAPES

Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals

2005; SAGE Publishing; Volume: 10; Issue: 1 Linguagem: Inglês

10.1177/135965350501000108

2040-2058

Giorgio Antonucci, Enrico Girardi, Alessandro Cozzi‐Lepri, Maria Rosaria Capobianchi, Giulia Morsica, P Pizzaferri, Nicoletta Ladisa, Laura Sighinolfi, Alessandro Chiodera, Mariacarmela Solmone, Eleonora Lalle, Giuseppe Ippolito, Antonella d’Arminio Monforte, F. Ancarani, Andrea Antinori, G. Antonucci, M Bonasso, Raffaele Bruno, MR Capobianchi, A. Cargnel, Alessandro Cozzi‐Lepri, Antonella d’Arminio Monforte, Andrea De Luca, Massimo Galli, Luisa Gennero, Enrico Girardi, F. Lipani, N Marino, Laura Milazzo, Giulia Morsica, Philipp Narciso, P Pizzaferri, Massimo Puoti, T. Santantonio, G Verucchi, M Montroni, Giorgio Scalise, MC Braschi, MS Del Prete, Umberto Tirelli, Roberta Cinelli, Gianni Pastore, Nicoletta Ladisa, Greg Suter, Claudio Arici, Francesco Chiodo, Vincenzo Colangeli, C. Fiorini, O. Coronado, Giampiero Carosi, GP Cadeo, Carlo Torti, C Minardi, Davide Bertelli, Gloria Montenegro Rizzardini, G Migliorino, Pe Manconi, P Piano, Teresa Ferraro, A Scerbo, Eligio Pizzigallo, Matteo D’Alessandro, Domenico Santoro, Luigi Pusterla, G Carnevale, D Galloni, Paola Viganò, Maurizio Mena, F Ghinelli, L Sighinolfi, F Leoncini, F. Mazzotta, Mattéo Pozzi, Sergio Lo Caputo, Gioacchino Angarano, Benvenuto Grisorio, Annalisa Saracino, Sergio Ferrara, Pierfrancesco Grima, Paolo Tundo, G Pagano, Giovanni Cassola, A. Alessandrini, R Piscopo, M Toti, Silvia Chigiotti, Fabrizio Soscia, L Tacconi, Anna Orani, P. Perini, A Scasso, M. A. Vincenti, F Chiodera, P. Castelli, Alfredo Scalzini, G Fibbia, M Moroni, Adriano Lazzarin, A. Cargnel, GM Vigevani, L Caggese, Antonella d’Arminio Monforte, Daniele Repetto, Roberto Novati, Andrea Galli, Stefania Merli, C Pastecchia, M C Moioli, Roberto Esposito, C Mussini, N Abrescia, Antonio Chirianni, C Izzo, M Piazza, M De Marco, Rosaria Viglietti, Elio Manzillo, Graf M, A Colomba, Vincenzo Abbadessa, Tullio Prestileo, Salvatrice Mancuso, Carlo Ferrari, P Pizzaferri, G. Filice, L. Minoli, Raffaele Bruno, Stefano Novati, F Baldelli, M Tinca, E. Petrelli, A Cioppi, F Alberici, Andrea Ruggieri, F. Menichetti, Canio Martinelli, C De Stefano, Ángela Gala, G. Ballardini, E Briganti, G. Magnani, M A Ursitti, M. Arlotti, P Ortolani, Roberto Cauda, F. Dianzani, Giuseppe Ippolito, Andrea Antinori, G. Antonucci, S. Delia, Philipp Narciso, Nicola Petrosillo, Vincenzo Vullo, Andrea De Luca, S Di Giambenedetti, Mauro Zaccarelli, R Acinapura, Patrizio De Longis, Maria Rosa Ciardi, Giampiero D’Offizi, MP Trotta, Pasquale Noto, Miriam Lichtner, MR Capobianchi, Enrico Girardi, Patrizio Pezzotti, G Rezza, MS Mura, M Mannazzu, Francesco Resta, K Loso, Pietro Caramello, Alessandro Sinicco, M L Soŕanzo, Giancarlo Orofino, Mariangela Sciandra, M Bonasso, PA Grossi, Claudia Basilico, A Poggio, Gabriella Bottari, Enzo Raise, S Pasquinucci, Fausto de Lalla, Giulia Tositti, A Cozzi Lepri,

HIV/AIDS drug development and treatment

The prognostic role of GB virus type C (GBV-C) viraemia in HIV-infected subjects treated with highly active antiretroviral therapy (HAART) is still undefined, The aim of this analysis is to assess the relationship between GBV-C infection and response to antiretroviral therapy among HIV-infected subjects initiating HAART when antiretroviral-naive. A prospective, observational study of 400 HIV-infected patients with measurements of GBV-C RNA, hepatitis C virus (HCV) antibodies and HCV RNA determined from plasma stored prior to HAART initiation, Time to virological (achieving HIV RNA ≤500 copies/ml) and immunological success (a CD4+ count increase of ≥200cells/μl), and the time to virological relapse (confirmed HIV RNA >500 copies/ml) were assessed by Kaplan-Meier methods and Cox proportional hazard regression model. Of the subjects, 117 (29.3%) were GBV-C positive and, overall, 351 (87.8%) patients achieved virological success, After controlling for a number of confounders including HCV RNA, GBV-C viraemic patients experienced a significantly lower risk of HIV rebound than those who were GBV-C negative [relative hazard (RH)=0.56, 95% CI: 0.34–0.93, P=0.03], Conversely, the probability of achieving initial virological success or CD4+ count response after HAART did not differ between GBV-C-negative and -positive subjects, These results suggest that GBV-C coinfection may play a role in determining the rate of HIV rebound possibly by competing with HIV replication after HIV load has been successfully suppressed by HAART.